Drugs for Female Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 86)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Toremifene |
Approved, Investigational |
Phase 4 |
|
89778-26-7 |
3005573 |
Synonyms:
Acapodene
Citrate, toremifene
Fareston
FARESTONE
FC-1157A
GTX-006
J33.157K
Toremifene
Toremifene Base
|
Toremifene citrate
Toremifene citrate (1:1)
Toremifene, (e)-isomer
Toremifeno
Toremifeno [Spanish]
Toremifenum
Toremifenum [Latin]
Z-Toremifene
|
|
2 |
|
Sevoflurane |
Approved, Vet_approved |
Phase 4 |
|
28523-86-6 |
5206 |
Synonyms:
1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane
Fluoromethyl hexafluoroisopropyl ether
Fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether
HFE-347MMZ1
MR6S4
MR-6S4
Sevofluran
SEVOFLURANE
|
Sevoflurano
Sevoflurano [INN-Spanish]
Sevofluranum
Sevofluranum [INN-Latin]
Sevorane
SOJOURN
Ultane
|
|
3 |
|
Propofol |
Approved, Investigational, Vet_approved |
Phase 4 |
|
2078-54-8 |
4943 |
Synonyms:
2,6 Diisopropylphenol
2,6-Bis(1-methylethyl)phenol
2,6-Diisopropylphenol
2,6-diisopropylphenol|Diprivan®|ICI 35868
Abbott brand OF propofol
Alpha Brand OF propofol
Aquafol
Astra brand OF propofol
AstraZeneca brand OF propofol
Braun brand OF propofol
Curamed brand OF propofol
Diisopropylphenol
Diprivan
Disoprivan
Disoprofol
Fresenius brand OF propofol
Fresenius kabi brand OF propofol
Fresofol
ICI 35868
ICI 35-868
|
ICI35,868
ICI-35868
Ivofol
Juste brand OF propofol
NSC-5105
Parnell brand OF propofol
Pisa brand OF propofol
Propofol
Propofol abbott
Propofol fresenius
Propofol MCT
Propofol rovi
Propofol-lipuro
Propofolum
Rapinovet
Recofol
Rovi brand OF propofol
Schering brand OF propofol
Zeneca brand OF propofol
|
|
4 |
|
Estrogen Receptor Modulators |
|
Phase 4 |
|
|
|
5 |
|
Selective Estrogen Receptor Modulators |
|
Phase 4 |
|
|
|
6 |
|
Platelet Aggregation Inhibitors |
|
Phase 4 |
|
|
|
7 |
|
Anesthetics, Intravenous |
|
Phase 4 |
|
|
|
8 |
|
Anesthetics, Inhalation |
|
Phase 4 |
|
|
|
9 |
|
Anesthetics, General |
|
Phase 4 |
|
|
|
10 |
|
Anesthetics |
|
Phase 4 |
|
|
|
11 |
|
Hypnotics and Sedatives |
|
Phase 4 |
|
|
|
12 |
|
Fulvestrant |
Approved, Investigational |
Phase 3 |
|
129453-61-8 |
17756771 104741 |
Synonyms:
(1S,9R,11S,14S,15S)-15-Methyl-9-[9-(4,4,5,5,5-pentafluoropentanesulphinyl)nonyl]tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-2,4,6-triene-5,14-diol
(7α,17β)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1(10),2,4-triene-3,17-diol
7-(9-(4,4,5,5,5-Pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol
Faslodex
Faslodex®|ICI 182,780|ICI 182780|ICI182780|ZD-9238
|
FULVESTRANT
ICI 182,780
ICI-182780
SID29215034
ZD-9238
|
|
13 |
|
Anastrozole |
Approved, Investigational |
Phase 3 |
|
120511-73-1 |
2187 |
Synonyms:
2,2'-(5-(1H-1,2,4-Triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile)
a,a,Alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
alpha,alpha,Alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
Anastrazole
Anastrole
Anastrozol
ANASTROZOLE
Arimidex
Arimidex®
Astra brand OF anastrozole
|
AstraZeneca brand OF anastrozole
ICI D1033
ICI-D1033
NASTROSA
ZD1033
ZD-1033
Zeneca brand OF anastrozole
Zeneca ZD 1033
Α,α,alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
α,α,α',α'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
|
|
14 |
|
Goserelin |
Approved |
Phase 3 |
|
65807-02-5 |
5311128 47725 |
Synonyms:
(2S)-1-[(2S)-2-{[(2S)-2-{[(2R)-3-(tert-butoxy)-2-{[(2S)-2-{[(2S)-1,3-dihydroxy-2-{[(2S)-1-hydroxy-2-{[(2S)-1-hydroxy-2-({hydroxy[(2S)-5-hydroxy-3,4-dihydro-2H-pyrrol-2-yl]methylidene}amino)-3-(1H-imidazol-5-yl)propylidene]amino}-3-(1H-indol-3-yl)propylidene]amino}propylidene]amino}-1-hydroxy-3-(4-hydroxyphenyl)propylidene]amino}-1-hydroxypropylidene]amino}-1-hydroxy-4-methylpentylidene]amino}-5-carbamimidamidopentanoyl]-N-[(C-hydroxycarbonimidoyl)amino]pyrrolidine-2-carboximidate
Acetate, goserelin
DECAPEPTIDE I
decapeptide I|ICI 118630|Zoladex®
Goserelin
Goserelin acetate
Goserelina
|
ICI 118
ICI 118630
ICI-118630
ICI-118630Zoladex
ZD9393
Zoladex
|
|
15 |
|
Letrozole |
Approved, Investigational |
Phase 3 |
|
112809-51-5 |
3902 |
Synonyms:
4,4'-(1H-1,2,4-Triazol-1-yl-methylene)-bis(benzonitrile)
CGS-20267
FEM345
Femara
Fémara
|
Femara®
Letrozol
LETROZOLE
Novartis brand OF letrozole
|
|
16 |
|
Antineoplastic Agents, Hormonal |
|
Phase 3 |
|
|
|
17 |
|
Estrogens |
|
Phase 3 |
|
|
|
18 |
|
Estrogen Receptor Antagonists |
|
Phase 3 |
|
|
|
19 |
|
Estrogen Antagonists |
|
Phase 3 |
|
|
|
20 |
|
Hormones |
|
Phase 3 |
|
|
|
21 |
|
Hormone Antagonists |
|
Phase 3 |
|
|
|
22 |
|
Aromatase Inhibitors |
|
Phase 3 |
|
|
|
23 |
|
Docetaxel |
Approved, Investigational |
Phase 2 |
|
114977-28-5 |
148124 |
Synonyms:
CKD-810
Docecad®|docetaxel anhydrous|EmDOC|Taxotere®
DOCEFREZ
DOCETAXEL
Docetaxel anhydrous
Docetaxel hydrate
Docetaxel trihydrate
Docetaxel, trihydrate
Docetaxol
N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol
|
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
NSC-628503
RP-56976
TAXCEUS
Taxoltere metro
Taxotere
TXL
XRP6976
|
|
24 |
|
Darbepoetin alfa |
Approved, Investigational |
Phase 2 |
|
209810-58-2 |
|
Synonyms:
ARANESP
ARANESP SURECLICK
Darbepoetin
DARBEPOETIN ALFA
Darbepoetin alfa,recombinant
Darbepoetina alfa
|
EPOETIN
ERYTHROPOIETIN PRECURSOR
KRN321
KRN-321
NESP
|
|
25 |
|
Tamoxifen |
Approved |
Phase 2 |
|
10540-29-1, 54965-24-1 |
2733526 |
Synonyms:
(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(Para-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine
1-Para-b-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-β-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-b-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-Β-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
Apo-tamox
Citofen
Citrate, tamoxifen
Crisafeno
Diemon
EMBLON
FENTAMOX 10
FENTAMOX 20
Gen-tamoxifen
I.C.I.46474 CITRATE
ICI-46474
ICI-46474|Nolvadex®|Soltamox®
ICI-47699
Istubol
KENTADEX
KESSAR
KESSAR 10
KESSAR 20
Noltam
Nolvadex
NOLVADEX D
NOLVADEX FTE
Nolvadex-D
Nourytam
|
Novaldex
Novo-Tamoxifen
OESTRIFEN-10
OESTRIFEN-20
OESTRIFEN-40
Oncomox
PMS-Tamoxifen
Retaxim
Savient brand OF tamoxifen citrate
Soltamox
Tamizam
Tamofen
Tamone
Tamoplex
Tamoxasta
Tamoxen
TAMOXIFEN
Tamoxifen citrate
Tamoxifene
TAMOXIFÈNE
Tamoxifene [INN-French]
Tamoxifeno
Tamoxifeno [INN-Spanish]
Tamoxifenum
Tamoxifenum [INN-Latin]
Tomaxithen
trans-Tamoxifen
Valodex
ZD6157
Zemide
Zitazonium
ZYNOPLEX
|
|
26 |
|
Donepezil |
Approved |
Phase 2 |
|
120014-06-4 |
3152 |
Synonyms:
1-Benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine hydrochloride
Aricept
Aricept odt
Aricept®|E-2020
Domepezil
Donaz
Donepezil
|
Donepezil hydrochloride
Donepezilium oxalate trihydrate
Donepezilo
Donepezilum
E-2020
Eranz
|
|
27 |
|
Epirubicin |
Approved |
Phase 2 |
|
56420-45-2 |
41867 |
Synonyms:
4' Epi adriamycin
4' Epi doxorubicin
4' Epi DXR
4' Epiadriamycin
4' Epidoxorubicin
4'-Epiadriamycin
4'-Epi-adriamycin
4'-Epidoxorubicin
4'-Epi-doxorubicin
4'-Epi-DXR
Cell pharm brand OF epirubicin
Ellence
EPI cell
Epiadriamycin
EPIcell
EPI-cell
Epidoxorubicin
Epi-Dx
Epilem
Epirubicin
Epirubicin hydrochloride
Epirubicina
Epirubicina [INN-Spanish]
Epirubicina [Spanish]
Epirubicine
|
Epirubicine [French]
Epirubicine [INN-French]
Epirubicinum
Epirubicinum [INN-Latin]
Epirubicinum [Latin]
Farmorubicin
Farmorubicina
Farmorubicine
Hydrochloride, epirubicin
IMI 28
IMI28
IMI-28
Kenfarma brand OF epirubicin hydrochloride
Lemery brand OF epirubicin hydrochloride
NSC-256942
Pfizer brand OF epirubicin hydrochloride
Pharmorubicin
Pharmorubicin Pfs
Pidorubicina
Pidorubicina [INN-Spanish]
Pidorubicine
Pidorubicine [INN-French]
Pidorubicinum
Pidorubicinum [INN-Latin]
Ridorubicin
|
|
28 |
|
Capecitabine |
Approved, Investigational |
Phase 2 |
|
154361-50-9 |
60953 |
Synonyms:
(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
Capecitabin
Capecitabina
CAPECITABINE
Capécitabine
Capecitabinum
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
PENTYL [1-(3,4-DIHYDROXY-5-METHYL-OXOLAN-2-YL)-5-FLUORO-2-OXO-PYRIMIDIN-4-YL]AMINOFORMATE
Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
|
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
R340
RO-091978000
RO-09-1978000
RO-09-1978-000
Ro-09-1978-000|Ro-091978000|Xeloda®
Xeloda
|
|
29 |
|
Palbociclib |
Approved, Investigational |
Phase 2 |
|
571190-30-2 |
5330286 |
Synonyms:
6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-D)pyrimidin-7-one
6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-{[5-(PIPERAZIN-1-YL)PYRIDIN-2-YL]AMINO}PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE
IBRANCE
Ibrance®|PD-0332991|PD0332991
PALBOCICLIB
|
PD 0332991
PD 332991
PD0332991
PD-0332991
UNII-g9Zf61le7g
|
|
30 |
|
Estradiol |
Approved, Investigational, Vet_approved |
Phase 2 |
|
50-28-2 |
5757 |
Synonyms:
(+)-3,17B-ESTRADIOL
(17b)-Estra-1,3,5(10)-triene-3,17-diol
(17BETA)-ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
(17Β)-ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
(1S,10R,11S,14S,15S)-15-METHYLTETRACYCLO[8.7.0.0^{2,7}.0^{11,15}]HEPTADECA-2,4,6-TRIENE-5,14-DIOL
(8R,9S,13S,14S,17S)-13-METHYL-6,7,8,9,11,12,14,15,16,17-DECAHYDROCYCLOPENTA[A]PHENANTHRENE-3,17-DIOL
[<sup>3</sup>H]-estradiol|[<sup>3</sup>H]-estrogen|[<sup>3</sup>H]E2|[<sup>3</sup>H]estradiol
13B-METHYL-1,3,5(10)-GONATRIENE-3,17B-OL
17 beta Estradiol
17 beta Oestradiol
17 beta-Estradiol
17 beta-Oestradiol
17b Oestradiol
17b-Estra-1,3,5(10)-triene-3,17-diol
17B-ESTRADIOL
17BETA OESTRADIOL
17BETA-ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
17BETA-ESTRADIOL
17BETA-OESTRADIOL
17B-OESTRADIOL
17Β oestradiol
17Β-ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
17β-estradiol
17Β-OESTRADIOL
3,17B-DIHYDROXYESTRA-1,3,5(10)-TRIENE
3,17B-ESTRADIOL
3,17-EPIDIHYDROXYESTRATRIENE
ADGYN ESTRO
AERODIOL
AGOFOLLIN
ALFATRADIOL
ALORA
ALTRAD
AMNESTROGEN
AQUADIOL
AQUAGEN
BARDIOL
BEDOL
B-ESTRADIOL
BETA-ESTRADIOL
CIS-ESTRADIOL
CLIMADERM
CLIMARA
CLIMARA PRO
COMPUDOSE
CORPAGEN
Delestrogen
DELTA-ESTRADIOL
DELTA-OESTRADIOL
DEPO-ESTRADIOL
DERMESTRIL
DERMESTRIL 100
DERMESTRIL 25
DERMESTRIL 50
DERMESTRIL SEPTEM 25
DERMESTRIL SEPTEM 50
DERMESTRIL SEPTEM 75
DESTRADIOL
D-ESTRADIOL
DIHYDROFOLLICULAR HORMONE
DIHYDROFOLLICULIN
DIHYDROMENFORMON
DIHYDROTHEELIN
DIHYDRO-THEELIN
DIHYDROXYESTRIN
DIMENFORMON
DIOGYN
DIOGYNETS
DIVIGEL
D-OESTRADIOL
E2
E2|estrogen|oestrodiol|oestrogen
E-CYPIONATE
ELESTRIM
ELESTRIN
ELLESTE SOLO
ELLESTE SOLO MX 40
ELLESTE SOLO MX 80
ENCORE
EPIESTRIOL 50
ESCLIM
ESTRA-1,3,5(10)-TRIENE-3,17B-DIOL
ESTRACE
ESTRADERM
ESTRADERM MX 100
ESTRADERM MX 25
ESTRADERM MX 50
ESTRADERM MX 75
ESTRADERM TTS
ESTRADERM TTS 100
ESTRADERM TTS 25
ESTRADERM TTS 50
ESTRADIOL
Estradiol 17 alpha
Estradiol 17 beta
Estradiol 17beta
Estradiol anhydrous
ESTRADIOL HEMIHYDRATE
Estradiol hemihydrate, (17 alpha)-isomer
Estradiol monohydrate
Estradiol orion brand
Estradiol valerate
Estradiol valeriante
|
Estradiol, (-)-isomer
Estradiol, (+-)-isomer
Estradiol, (16 alpha,17 alpha)-isomer
Estradiol, (16 alpha,17 beta)-isomer
Estradiol, (17-alpha)-isomer
Estradiol, (8 alpha,17 beta)-(+-)-isomer
Estradiol, (8 alpha,17 beta)-isomer
Estradiol, (9 beta,17 alpha)-isomer
Estradiol, (9 beta,17 beta)-isomer
Estradiol, monosodium salt
Estradiol, sodium salt
Estradiol-17 alpha
Estradiol-17 beta
Estradiol-17b
ESTRADIOL-17BETA
ESTRADIOL-17-BETA
Estradiol-17β
ESTRADIOLUM
ESTRADOT
ESTRALDINE
ESTRASORB
ESTRING
ESTRING VAGINAL RING
ESTROCLIM
ESTROCLIM 50
ESTROGEL
ESTROGEL HBF
ESTROGEN
ESTROVITE
EVAMIST
EVOREL
EVOREL 100
EVOREL 25
EVOREL 50
EVOREL 75
FEMATRIX 40
FEMATRIX 80
FEMESTRAL
FEMOGEN
FEMPATCH
FEMSEVEN 100
FEMSEVEN 50
FEMSEVEN 75
FOLLICYCLIN
GELESTRA
GINOSEDOL
GVNODIOL
GYNERGON
GYNODIOL
GYNOESTRYL
GYNOGEN
IMVEXXY
INNOFEM
LAMDIOL
MACRODIOL
MENOREST
MENOREST 37.5
MENOREST 50
MENOREST 75
MENORING 50
MENOSTAR
MINIVELLE
NORDICOL
Novartis pharmaceuticals brand OF estradiol
NSC-20293
NSC-9895
OESCLIM
OESTERGON
OESTRA-1,3,5(10)-TRIENE-3,17B-DIOL
OESTRADIOL
OESTRODIOL
OESTROGEL
OESTROGEN
OESTROGLANDOL
Orion brand OF estradiol
OVAHORMON
OVASTEROL
OVASTEVOL
OVOCYCLIN
OVOCYLIN
PERLATANOL
PRIMOFOL
PROFOLIOL
PROFOLIOL B
PROGYNON
Progynon depot
PROGYNON DH
Progynon-depot
Progynova
PROGYNOVA TS
SANDRENA
SANDRENA 1
SYNDIOL
SYSTEN
VAGIFEM
VAGIFEM 18
VAGIFEM 8
VIVELLE
VIVELLE-DOT
WC3011
WC-3011
ZUMENON
Β-estradiol
|
|
31 |
|
Polyestradiol phosphate |
Approved |
Phase 2 |
|
28014-46-2 |
|
Synonyms:
(17-beta)-Estra-1,3,5(10)-triene-3,17-diol polymer with phosphoric acid
ESTRADIOL PHOSPHATE
Estradiol phosphate polymer
ESTRADURIN
Fosfato de poliestradiol
LEO-114
Oestradiol phosphate polymer
|
Phosphate de polyestradiol
Poly(estradiol phosphate)
POLYEST PHOS
POLYESTRADIOL PHOS PHOSPHATE
POLYESTRADIOL PHOSPHATE
Polyestradioli phosphas
|
|
32 |
|
Neurotransmitter Agents |
|
Phase 2 |
|
|
|
33 |
|
Cholinergic Agents |
|
Phase 2 |
|
|
|
34 |
|
Antimitotic Agents |
|
Phase 2 |
|
|
|
35 |
|
Tubulin Modulators |
|
Phase 2 |
|
|
|
36 |
|
Epoetin Alfa |
|
Phase 2 |
|
|
|
Synonyms:
BINOCRIT
EPO
EPOETIN ALFA
EPOGEN
|
EPREX
ERYTHROPOIETIN PRECURSOR
PROCRIT
|
|
37 |
|
Hematinics |
|
Phase 2 |
|
|
|
38 |
|
Nootropic Agents |
|
Phase 2 |
|
|
|
39 |
|
Cholinesterase Inhibitors |
|
Phase 2 |
|
|
|
40 |
|
Antimetabolites |
|
Phase 2 |
|
|
|
41 |
|
Protein Kinase Inhibitors |
|
Phase 2 |
|
|
|
42 |
|
Estradiol 3-benzoate |
|
Phase 2 |
|
|
|
43 |
|
Estradiol 17 beta-cypionate |
|
Phase 2 |
|
|
|
44 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 1 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(+-)-Cyclophosphamide
(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
(RS)-Cyclophosphamide
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
Ciclofosfamida
Ciclofosfamide
Clafen
Claphene
CP
CPA
CTX
CY
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamidum
Cyclophosphan
Cyclophosphane
Cyclophosphoramide
|
Cyclostin
Cyklofosfamid
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan Lyoph
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
Genoxal
Hexadrin
LEDOXINA
Lyophilized Cytoxan
Mitoxan
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
Neosar
Procytox
Rcra Waste Number U058
Revimmune
Semdoxan
Sendoxan
Senduxan
Zyklophosphamid
|
|
45 |
|
Doxorubicin |
Approved, Investigational |
Phase 1 |
|
23214-92-8 |
31703 |
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
ADM
ADR
Adriablastin
Adriablastine
Adriamycin
Adriamycin PFS
Adriamycin RDF
Adriamycin Semiquinone
Adriamycin®|Caelyx® (liposomal doxorubicin)|Doxil®|doxorubicin hydrochloride
Adriblastin
Adriblastina
Adriblastine
Adrimedac
Baxter brand OF doxorubicin hydrochloride
Bedford brand OF doxorubicin hydrochloride
Bristol-myers squibb brand OF doxorubicin hydrochloride
Caelyx
Cell pharm brand OF doxorubicin hydrochloride
Columbia brand OF doxorubicin hydrochloride
DM2
DOXIL
Doxo
Doxo cell
Doxo-cell
Doxolem
DOXORUBICIN
Doxorubicin HCl
Doxorubicin hexal
Doxorubicin hydrochloride
|
Doxorubicin NC
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicina ferrer farm
Doxorubicina funk
Doxorubicina tedec
Doxorubicine
Doxorubicine [INN-French]
Doxorubicine baxter
Doxorubicinum
Doxorubicinum [INN-Latin]
Doxotec
Elan brand OF doxorubicin hydrochloride
Farmiblastina
Ferrer brand OF doxorubicin hydrochloride
Hexal brand OF doxorubicin hydrochloride
Hydrochloride, doxorubicin
HYDROXYDAUNORUBICIN
Kenfarma brand OF doxorubicin hydrochloride
Lemery brand OF doxorubicin hydrochloride
Medac brand OF doxorubicin hydrochloride
Myocet
Neocorp brand OF doxorubicin hydrochloride
NSC-123127
Onkodox
Onkoworks brand OF doxorubicin hydrochloride
Pfizer brand OF doxorubicin hydrochloride
Prasfarma brand OF doxorubicin hydrochloride
RDF Rubex
Resmycin
Ribodoxo
Ribosepharm brand OF doxorubicin hydrochloride
Rubex
Tedec meiji brand OF doxorubicin hydrochloride
Urokit doxo cell
Urokit doxo-cell
VALRUBICIN IMPURITY, DOXORUBICIN
|
|
46 |
|
Alkylating Agents |
|
Phase 1 |
|
|
|
47 |
|
Antirheumatic Agents |
|
Phase 1 |
|
|
|
48 |
|
Antineoplastic Agents, Alkylating |
|
Phase 1 |
|
|
|
49 |
|
Immunosuppressive Agents |
|
Phase 1 |
|
|
|
50 |
|
Immunologic Factors |
|
Phase 1 |
|
|
|
Interventional clinical trials:
(show all 45)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Evaluation of Adjuvant Endocrine Therapy for Operable ER-beta Positive, ER-alpha/PR Negative, Her-2 Negative Breast Cancer Patients |
Unknown status |
NCT02089854 |
Phase 4 |
Toremifene; Anastrozole |
2 |
Does Anesthesia Technique Affect the Presence of Circulating Tumor Cells in Primary Breast Carcinoma? A Randomised Controlled Trial. |
Completed |
NCT02005770 |
Phase 4 |
Sevoflurane;Propofol |
3 |
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of FCN-437c Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer |
Recruiting |
NCT05438810 |
Phase 3 |
FCN-437c,Fulvestrant,Goserelin acetate;Placebo,Fulvestrant,Goserelin acetate |
4 |
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR-positive and HER2-negative Advanced Breast Cancer |
Recruiting |
NCT05439499 |
Phase 3 |
FCN-437c, Letrozole or anastrozole, Goserelin acetate;Placebo, Letrozole or anastrozole, Goserelin acetate |
5 |
A Multicenter, Randomized, Double-blind Phase III Study:SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage,Female Breast Cancer |
Enrolling by invitation |
NCT04842617 |
Phase 3 |
SHR6390;placebo |
6 |
Phase II Study of Dose-Dense TC (Docetaxel + Cyclophosphamide) With Pegfilgrastim Support for Adjuvant Therapy of pN0, pN1 or Nx Breast Cancer |
Completed |
NCT01671319 |
Phase 2 |
docetaxel + cyclophosphamide + pegfilgrastim |
7 |
An Open-Label, Randomized Phase 2 Study to Validate a Patient Satisfaction Questionnaire for Anemia Treatment in Female Breast Cancer Patients Treated With Darbepoetin Alfa or Recombinant Human Erythropoietin for Anemia Due to Chemotherapy |
Completed |
NCT00120692 |
Phase 2 |
Darbepoetin Alfa;Recombinant Human Erythropoietin |
8 |
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Q-122 for the Treatment of Vasomotor Symptoms in Female Breast Cancer Patients/Survivors Taking Tamoxifen or an Aromatase Inhibitor |
Completed |
NCT03518138 |
Phase 2 |
Q-122;Placebo |
9 |
A Feasibility Study of Donepezil in Female Breast Cancer Survivors With Self-Reported Cognitive Dysfunction Following Chemotherapy |
Completed |
NCT01466270 |
Phase 2 |
donepezil hydrochloride;Placebo |
10 |
Differential Gene Regulation During Neoadjuvant Therapy Trial of Epirubicin/Cyclophosphamide (EC) vs Docetaxel/Capecitabine (DX) Regimens in Patients With Large ER-positive and ER-negative Breast Cancers: A Randomized Phase II Trial. |
Completed |
NCT01869192 |
Phase 2 |
Epirubicin;Cyclophosphamide;Docetaxel;Capecitabine |
11 |
An Open-Label, Single-Arm, Phase 2 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery |
Completed |
NCT03113825 |
Phase 2 |
AVB-620 |
12 |
Pilot Trial of Anastrozole and Palbociclib as First-Line Therapy and as Maintenance Therapy After First Line Chemotherapy in Hormone Receptor Positive, HER2-Negative Postmenopausal Metastatic Breast Cancer |
Active, not recruiting |
NCT02942355 |
Phase 2 |
anastrozole;Palbociclib |
13 |
An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in Women With Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy |
Terminated |
NCT02540330 |
Phase 2 |
Fulvestrant |
14 |
A Phase II Study of High Dose Estradiol in Metastatic Triple Negative Breast Cancer |
Terminated |
NCT01083641 |
Phase 2 |
Estradiol |
15 |
Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer. Phase I Feasibility Study of Hifu-Induced Hyperthermia, LTLD and Cyclophosphamide for Metastatic Breast Cancer |
Recruiting |
NCT03749850 |
Phase 1 |
LTLD;Cyclophosphamide |
16 |
Effect of Yoga on Life Quality and Immunity in Breast Cancer Patients After Operation and or Chemotherapy |
Unknown status |
NCT02243163 |
|
|
17 |
Clinical Cohort of Individual Expectations, Side Effects, Quality of Life and Adherence in Postoperative Women With Estrogen Receptor Positive Breast Cancer During Endocrine Therapy |
Unknown status |
NCT02088710 |
|
|
18 |
A Prospective, Randomized, Controlled Trial to Compare the Effect of TIVA Propofol vs Sevoflurane Anaesthetic on Serumserum Biomarkers and on PBMCs in Patients Undergoing Breast Cancer Resection Surgery |
Unknown status |
NCT03005860 |
|
2,6-Diisopropylphenol;Fluoromethyl hexafluoroisopropyl ether;Fentanyl Citrate;Atracurium Besylate |
19 |
Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens |
Unknown status |
NCT02480933 |
|
|
20 |
Evaluating Female Sexual Dysfunction in Breast Cancer Patients After Mastectomy |
Unknown status |
NCT03153631 |
|
|
21 |
Clinical Application of Nocebo Research: Optimizing Expectations of Breast Cancer Patients to Prevent Nocebo Side Effects and Decrease of Quality of Life During Adjuvant Endocrine Therapy (DFG, NE 1635/2-1) |
Unknown status |
NCT01741883 |
|
|
22 |
Text for Health: Integrating Technology and Health Communication to Improve Health Outcomes (Part 2 of 2) |
Completed |
NCT04290585 |
|
|
23 |
Phase 1. Collect Samples of Breast Biopsy Patients Treated at the Hospital Radiology Service Maternal Perinatal Monica Pretelini |
Completed |
NCT01643148 |
|
|
24 |
Metabolic Syndrome and Female Breast Cancer: a Case-control Study in Southern Brazil |
Completed |
NCT02282592 |
|
|
25 |
Synbiotic Supplementation to Reduce Anxiety Symptoms in Female Breast Cancer Survivors and/or Their Female Relatives |
Completed |
NCT04784182 |
|
|
26 |
Effects of a Traditional Chinese Exercise Program- Tai Chi on Symptom Cluster of Fatigue-sleep Disturbance-depression in Female Breast Cancer Patients: a Preliminary Randomized Controlled Trial |
Completed |
NCT04190342 |
|
|
27 |
Trends of Mastectomy and Breast-Conserving Surgery and Related Factors in Female Breast Cancer Patients Treated at King Abdulaziz University Hospital, Jeddah, Saudi Arabia, 2009-2017 |
Completed |
NCT03762642 |
|
|
28 |
The Effects of Auricular Acupressure on Chemotherapy-Induced Nausea and Vomiting in Female Breast Cancer Patients: A Pilot Randomized Controlled Trial |
Completed |
NCT02403037 |
|
Standard anti-emetic treatment (5-HT3 receptor antagonists and/or Dexamethasone) |
29 |
Effect of Cryotherapy on Paclitaxel-Induced Peripheral Neuropathy of the Hand in Female Breast Cancer Patients: A Prospective Self-Controlled Study |
Completed |
NCT05138042 |
|
|
30 |
The Treatment For Recurrent Female Breast Cancer After Initial Endocrine Therapy Among Taiwanese Population |
Completed |
NCT02924584 |
|
|
31 |
Ultra-hypofractionated Adjuvant Radiotherapy After Breast Conserving Surgery in Breast Cancer Patients |
Recruiting |
NCT05586256 |
|
|
32 |
Exercise, Gut Microbiome, and Breast Cancer: Increasing Reach to Underserved Populations |
Recruiting |
NCT05000502 |
|
|
33 |
Efficacy of a Brief Intervention for Female Breast CANcer Based on Acceptance and Commitment Therapy (I-CAN-ACT) for Depression and Physical Pain: A 2-Arm Randomized Clinical Trial |
Recruiting |
NCT05374161 |
|
|
34 |
A Pilot Feasibility Study of a Gratitude Journaling Intervention to Enhance Well-being and Exercise Readiness in Older African American Female Breast Cancer Survivors |
Recruiting |
NCT05473026 |
|
|
35 |
Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT): a Multicenter, Observational Clinical Trial |
Recruiting |
NCT04985032 |
|
|
36 |
Intervention to Promote Uptake of Cancer Risk Counseling for Underserved Latinas |
Active, not recruiting |
NCT01230346 |
|
|
37 |
Place of Comprehensive Geriatric Assessment (CGA) in Patients ≥ 75 Years Care, With Breast Cancer, After Screening With FOG (Oncology Geriatric Filter): Comparison Between CGA Before Surgery (Strategy A) vs. After Surgery (Strategy B) |
Active, not recruiting |
NCT03059875 |
|
|
38 |
Monocentric, Randomized Clinical Trial About the Effect of Yoga Practice on QOL, Physiological Distress and Fatigue, on Patients Affected by Breast Cancer Undergoing Adjuvant Radiotherapy |
Active, not recruiting |
NCT04775290 |
|
|
39 |
A Phase III, Randomized, Single Blind, Attention Controlled, Multi-center Study of the Effects of a Rehabilitation Intervention on Participation Restrictions of Female Breast Cancer Survivors |
Active, not recruiting |
NCT03915548 |
|
|
40 |
Diagnostic Value of Digital Breast Tomosymthesis for Breast Mass Lesions Characterization |
Not yet recruiting |
NCT04863833 |
|
|
41 |
Endocrine Therapy-Induced Alopecia Natural History Evaluation Among Female Breast Cancer Survivors |
Not yet recruiting |
NCT05612100 |
|
|
42 |
Breast Cancer in Young Women: Is it Different? |
Suspended |
NCT01320488 |
|
|
43 |
Acupuncture for Joint Symptoms in Patients With Breast Cancer: A Randomised Controlled Trial |
Terminated |
NCT03836872 |
|
|
44 |
The Process and Outcomes of Treatment Decision-Making Communication Between Oncologists and Newly Diagnosed Female Breast-Cancer Patients |
Terminated |
NCT00891969 |
|
|
45 |
The Efficacy of Reduced-exertion High-intensity Interval Training for Improving Health and Well-being in Newly Diagnosed Female Breast Cancer Patients |
Withdrawn |
NCT03176888 |
|
|
|